LUND, Sweden, Oct. 28, 2021 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia"), a diagnostic company that develops and sells highly
accurate blood tests for the early detection of cancer, today
announced that Thomas King, MD, PhD,
Medical Director of Immunovia, Inc. was awarded the Presidential
Poster Award at the American College of Gastroenterology (ACG)
Annual Scientific Meeting for the pivotal blind validation results
for the IMMray™ PanCan-d test.
The abstract reports the results of Immunovia, Inc.'s blind
validation study, demonstrating that the IMMray™ PanCan-d test can
identify stage I & II pancreatic ductal adenocarcinoma (PDAC)
with 89% sensitivity and 99% specificity. The full abstract, along
with an audio presentation by Dr. Thomas
King, can be viewed here.
"It is very positive that Immunovia has received the ACG
Presidential Poster Award. ACG is a recognized leader in educating
gastrointestinal professionals and this shows how important our
IMMray™ PanCan-d test is to the medical community, and the
contribution it can make to the early detection of pancreatic
cancer. The ACG Presidential Poster Award is also a significant
step in building our dossiers that will contribute to our
discussions with payers to achieve reimbursement for the test",
said Patrik Dahlen, CEO of
Immunovia.
According to the ACG, "each year less than 5% of accepted
abstracts receive this distinction for high quality, novel, unique,
and interesting research". The ACG Abstract Selection Committee is
responsible for determining which abstracts receive the
Presidential Poster Award. Over 3100 posters are listed in the ACG
online ePoster Hall.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
PanDIA-1.
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
2021.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-receives-presidential-poster-award-at-the-american-college-of-gastroenterology-annual-scie,c3442202
The following files are available for download:
https://mb.cision.com/Main/13121/3442202/1487706.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/immunovia-receives-presidential-poster-award-at-the-american-college-of-gastroenterology-annual-scientific-meeting-301410684.html
SOURCE Immunovia AB